For instance, triple-negative breast cancer may be treated with drugs like pembrolizumab28 and sacituzumab govitecan,29 while HER2-positive breast cancer exhibited high response rates to trastuzumab deruxtecan30 and tucatinib.31 This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.